Extended Data Fig. 6: TRM-IFNG signature is superior in predicting the survival of stage III/IV melanoma patients.
a, Kaplan–Meier overall survival curves of melanoma patients from two different published datasets, GSE54467 (top, n=75 patients) and GSE19324 (bottom, n=44 patients), stratified by enrichment of signatures derived from each of three TRM clusters. High and low groups were separated by the median value of the Z-transformed normalized mean expression of each gene set (top: N= 37 patients high and N=38 patients low; bottom: N=22 patients high and N=22 patients low). P-values were calculated by two-sided log-rank test. OR P-values were calculated by multivariate Cox regression. b, Multivariable cox survival regression model evaluating the individual contribution of different variables to the prognosis of melanoma patients from the above datasets, GSE54467 (left) and GSE19324 (right). Forest plots show the means of hazard ratios (HRs) represented by blue squares, the 95% confidence intervals of HRs represented by horizontal bars, and p-values calculated by the two-sided Wald test for each variable.
